Evidence map›Paper›PMID 34202683›Full record

ReviewInternational journal of molecular sciences2021

Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies.

Elisa Lepore, Rosa Lauretta, Marta Bianchini, Marilda Mormando, Cherubino Di Lorenzo, Vittorio Unfer

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
6.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 41 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Microbiota modulation by teriflunomide therapy in people with multiple sclerosis: An observational case-control study.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2024
    Observational
  12. Article
  13. Article
  14. Article
  15. Review
  16. Inositol in Disease and Development: Roles of Catabolism viaInternational journal of molecular sciences · 2023
    Article
  17. Review
  18. Cells · 2022
    Article
  19. Harnessing the Power of Purple Sweet Potato Color andInternational journal of molecular sciences · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Elisa LeporeR&D Department, Lo.Li. Pharma, 00156 Rome, Italy.
Rosa LaurettaOncological Endocrinology Unit IRCCS Regina Elena National Cancer Institute, 00128 Rome, Italy.
Marta BianchiniOncological Endocrinology Unit IRCCS Regina Elena National Cancer Institute, 00128 Rome, Italy.
Marilda MormandoOncological Endocrinology Unit IRCCS Regina Elena National Cancer Institute, 00128 Rome, Italy.
Cherubino Di LorenzoDepartment of Medico-Surgical Sciences and Biotechnologies, La Sapienza University Polo Pontino, 04100 Latina, Italy.ORCID 0000-0003-0845-5694
Vittorio UnferThe Experts Group on Inositol in Basic and Clinical Research (EGOI), 00161 Rome, Italy.
Istituti di Ricovero e Cura a Carattere Scientifico · ITEuropean Gravitational Observatory · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inositols are natural molecules involved in several biochemical and metabolic functions in different organs and tissues. The term "inositols" refers to five natural stereoisomers, among which myo-Inositol (myo-Ins) is the most abundant one. Several mechanisms contribute to regulate cellular and tissue homeostasis of myo-Ins levels, including its endogenous synthesis and catabolism, transmembrane transport, intestinal adsorption and renal excretion. Alterations in these mechanisms can lead to a reduction of inositols levels, exposing patient to several pathological conditions, such as Polycystic Ovary Syndrome (PCOS), hypothyroidism, hormonal and metabolic imbalances, like weight gain, hyperinsulinemia, dyslipidemia, and metabolic syndrome. Indeed, myo-Ins is involved in different physiological processes as a key player in signal pathways, including reproductive, hormonal, and metabolic modulation. Genetic mutations in genes codifying for proteins of myo-Ins synthesis and transport, competitive processes with structurally similar molecules, and the administration of specific drugs that cause a central depletion of myo-Ins as a therapeutic outcome, can lead to a reduction of inositols levels. A deeper knowledge of the main mechanisms involved in cellular inositols depletion may add new insights for developing tailored therapeutic approaches and shaping the dosages and the route of administration, with the aim to develop efficacious and safe approaches counteracting inositols depletion-induced pathological events.

Indexed as

Carbohydrate MetabolismAnimalsBiological TransportBiosynthetic PathwaysDietary SupplementsGastrointestinal AbsorptionGastrointestinal MicrobiomeHumansInositolKidneyInositold-chiro-Inositoldepletiondietary supplementationmyo-Inositol

Identifiers

PMID34202683
PMCPMC8268915
OpenAlexW3176001959

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.